Skip to main content

Table 4 Predictive factors for overall survival

From: Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma

Factors

Median survival (months)

P value

Univariate analysis

Multivariate analysis

Age (years)

 

0.821

 

  ≤ 67

8.5 ± 5.5

  

  > 67

7.2 ± 4.7

  

Gender

 

0.225

 

 Male

8.5 ± 6.2

  

 Female

6.3 ± 2.8

  

ECOG score

 

<0.001

0.012

 0–1

9.5 ± 7.2

  

 2

3.8 ± 1.6

  

Etiology

 

0.153

 

 Viral

8.5 ± 5.5

  

 Non-viral

6.6 ± 5.5

  

Child-Pugh class

 

<0.001

0.026

 A

8.5 ± 7.2

  

 B

5.2 ± 1.6

  

AFP (ng/ml)

 

0.890

 

  ≤ 400

8.5 ± 6.2

  

  > 400

7.2 ± 2.8

  

Albumin (g/dL)

 

0.003

0.076

  ≤ 3.6

6.6 ± 2.8

  

  > 3.6

15.2 ± 6.2

  

Hemoglobin (g/dL)

 

0.141

 

  ≤ 11

6.6 ± 5.2

  

  > 11

9.5 ± 6.2

  

PVTT

 

0.541

 Yes

10.2 ± 5.5

  

 No

6.6 ± 4.7

  

BED (Gy10)

 

0.836

 

  ≤ 65.5

7.2 ± 5.5

  

  > 65.5

15.1 ± 1.6

  

RT duration (days)

 

0.443

 

  ≤ 37

8.5 ± 5.5

  

  > 37

7.8 ± 2.8

  

Tumor response

 

<0.001

0.016

 Yes

27.8 ± 8.5

  

 No

6.2 ± 2.8

  

Local control

 

0.007

0.011

 Yes

13.2 ± 4.8

  

 No

7.3 ± 2.6

  
  1. PVTT portal vein tumor thrombus, HCC hepatocellular carcinoma, ECOG Eastern Cooperative Oncology Group, BED biologically effective dose, SD standard deviation, AFP Alpha-fetoprotein